Novamind to Present at Life Sciences Investor Forum Print E-mail
Wednesday, 15 September 2021 03:35


TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Life Sciences Investor Forum, taking place virtually on Thursday, September 16 at 12:00 PM EST.

Join Novamind’s Chief Medical Officer and Director, Dr. Reid Robison, live as he presents the Company’s model for scaling access to psychedelic medicine through a multi-state, U.S. expansion of leading psychiatry clinics and clinical research sites. Investors are invited to participate in an open Q&A session following the presentation.

An archived webcast will be made available for attendees who are not able to join the event live.

Click here to join the webcast.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Contact Information  Novamind  Yaron Conforti, CEO and Director  Telephone: +1 (647) 953 9512    Samantha DeLenardo, VP, Communications  Email: [email protected]    Bill Mitoulas, Investor Relations  Email: [email protected]

Primary Logo

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!